What is the 13F Pro Quality Score for ALHC?

13F Pro ranks Alignment Healthcare, Inc. (ALHC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALHC's current score at https://13fpro.ai/research/ALHC (free sign-up required for the full ranking).

Which hedge funds own the most ALHC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ALHC include WELLINGTON MANAGEMENT GROUP LLP, FMR, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ALHC as soon as new 13F filings post.

Where does 13F Pro source ALHC data?

All Alignment Healthcare, Inc. fundamentals and ownership data come directly from SEC EDGAR. Alignment Healthcare, Inc. files with the SEC under CIK 1832466. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALHC in?

Alignment Healthcare, Inc. (ALHC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALHC research updated on 13F Pro?

ALHC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Alignment Healthcare, Inc.(ALHC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1832466 ALHC stock profile & AI dashboard →

13F Pro Quality Score

63.0/100

Rank #703 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

91.5/100

Profitability

55.9/100

Balance Sheet

51.6/100

Earnings Quality

30.0/100

Free Cash Flow

55.8/100

Institutional Flow

45.5/100

Revenue Scale

75.4/100

Dilution Risk

45.8/100

ALHC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Alignment Healthcare, Inc. (ALHC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALHC at 63.0/100 on a 32-signal composite quality model, placing it at rank #703 of 2,879 stocks — the top 25% of the AI-ranked universe. ALHC scores in the top quartile across revenue growth (91.5), revenue scale (75.4). Areas of concern include earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 45.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Alignment Healthcare, Inc. reports quarterly revenue of $1.2B, net income of $11.4M, an operating margin of 1.3%. Top institutional holders of ALHC by reported 13-F value include WELLINGTON MANAGEMENT GROUP LLP, FMR, BlackRock,, based on the most recent SEC filings. ALHC trades on the Nasdaq exchange and files with the SEC under CIK 1832466. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALHC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alignment Healthcare, Inc. directly from SEC EDGAR. Alignment Healthcare, Inc.'s 13F Pro composite quality score has ranged between 8 and 80 since 2022, currently 63.0 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

Revenue

Q1 2026

$1.2B

Net Income

Q1 2026

$11.4M

Free Cash Flow

Q1 2026

$121.3M

Operating Margin

Q1 2026

1.3%

ROIC

Q1 2026

2.9%

D/E Ratio

Q1 2026

1.56

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+46.1% YoY

$3.95BFY 2025

FY22 $1.43BFY23 $1.82BFY24 $2.70BFY25 $3.95B

Net Income

+99.4% YoY

$-724.0KFY 2025

FY22 $-149.5MFY23 $-148.0MFY24 $-128.0MFY25 $-724.0K

Operating Income

+114.5% YoY

$14.8MFY 2025

FY22 $-128.6MFY23 $-127.8MFY24 $-101.6MFY25 $14.8M

EPS (Diluted)

+100.0% YoY

$0.00FY 2025

FY22 $-0.83FY23 $-0.79FY24 $-0.67FY25 $0.00

Total Assets

+36.3% YoY

$1.07BFY 2025

FY22 $633.9MFY23 $591.9MFY24 $782.1MFY25 $1.07B

Total Debt

+0.5% YoY

$323.2MFY 2025

FY22 $160.9MFY23 $161.8MFY24 $321.4MFY25 $323.2M

Op. Cash Flow

+302.4% YoY

$139.9MFY 2025

FY22 $-45.4MFY23 $-59.2MFY24 $34.8MFY25 $139.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$3.95B +46.1%	$2.70B +48.3%	$1.82B +27.2%	$1.43B +22.8%	$1.17B +54.3%	$757.0M
Net Income	$-724.0K +99.4%	$-128.0M +13.5%	$-148.0M +1.0%	$-149.5M +23.4%	$-195.3M -336.6%	$-44.7M
Operating Income	$14.8M +114.5%	$-101.6M +20.5%	$-127.8M +0.6%	$-128.6M +27.8%	$-178.1M -504.0%	$-29.5M
EPS (Diluted)	$0.00 +100.0%	$-0.67 +15.2%	$-0.79 +4.8%	$-0.83 +27.2%	$-1.14	—
Total Assets	$1.07B +36.3%	$782.1M +32.1%	$591.9M -6.6%	$633.9M +0.5%	$630.9M	—
Total Debt	$323.2M +0.5%	$321.4M +98.6%	$161.8M +0.6%	$160.9M +6.8%	$150.6M	—
Operating Cash Flow	$139.9M +302.4%	$34.8M +158.7%	$-59.2M -30.3%	$-45.4M +42.3%	$-78.8M -955.5%	$9.2M

AI Insight: ALHC Financial Trends

ALHC delivered 33% revenue growth in Q1 2026 while achieving profitability turnaround from consistent losses through Q1 2025.

• Revenue surged 33% from $927M in Q1 2025 to $1,235M in Q1 2026, marking sustained growth acceleration.

• Operating income turned positive at $16M in Q1 2026 after operating losses through Q1 2025.

• Equity strengthened from $124M in Q2 2024 to $207M in Q1 2026, improving balance sheet foundation.

⚠ Operating cash flow volatility with -$50M in Q4 2025 followed by $129M rebound in Q1 2026.

⚠ Total debt increased from $212M to $324M over the period, raising leverage concerns despite equity growth.

AI Insight: ALHC Ratio Trends

ALHC achieved dramatic turnaround from deep losses in 2024 to positive profitability, with operating margin reaching 1.3% in Q1 2026.

• Operating margin improved from -3.2% in Q4 2024 to 1.3% in Q1 2026, marking sustained recovery from operational losses.

• ROE swung from -124.6% in Q4 2024 to 22.1% in Q1 2026, reflecting strong earnings recovery.

• Debt-to-equity ratio declined from peak of 3.22 in Q4 2024 to 1.56 in Q1 2026, indicating improving leverage.

⚠ Profitability remains volatile with negative margins in Q4 2025 despite overall improvement trend since 2024 lows.

⚠ ROIC turned negative again to -8.2% in Q4 2025 after reaching 19.6% in Q2 2025, showing inconsistent capital efficiency.

Get alerted when ALHC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alignment Healthcare, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALHC

WELLINGTON MANAGEMENT GROUP LLP
$301.3M17,098,936 sh
FMR LLC
$280.0M15,892,064 sh
BlackRock, Inc.
$248.0M14,075,197 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$171.1M9,710,071 sh
VANGUARD CAPITAL MANAGEMENT LLC
$140.5M7,973,663 sh
Invesco Ltd.
$123.3M7,000,099 sh
Hood River Capital Management LLC
$106.7M6,054,477 sh
CITADEL ADVISORS LLC
$94.5M5,362,666 sh
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$91.9M5,214,614 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$85.9M61,000,000 sh

Fund	Value	Shares
WELLINGTON MANAGEMENT GROUP LLP	$301.3M	17,098,936
FMR LLC	$280.0M	15,892,064
BlackRock, Inc.	$248.0M	14,075,197
VANGUARD PORTFOLIO MANAGEMENT LLC	$171.1M	9,710,071
VANGUARD CAPITAL MANAGEMENT LLC	$140.5M	7,973,663
Invesco Ltd.	$123.3M	7,000,099
Hood River Capital Management LLC	$106.7M	6,054,477
CITADEL ADVISORS LLC	$94.5M	5,362,666
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$91.9M	5,214,614
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$85.9M	61,000,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALHC on your watchlist

Track score changes the day Alignment Healthcare, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALHC a good stock to buy?

13F Pro's AI-powered analysis of Alignment Healthcare, Inc. (ALHC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALHC are available on the ALHC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ALHC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALHC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alignment Healthcare, Inc.'s investment landscape.